Woodstock Corp Sells 982 Shares of Amgen Inc. (NASDAQ:AMGN)

Woodstock Corp reduced its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 6.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,918 shares of the medical research company's stock after selling 982 shares during the period. Woodstock Corp's holdings in Amgen were worth $4,336,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of AMGN. Centricity Wealth Management LLC bought a new position in shares of Amgen during the 4th quarter worth about $25,000. Pinney & Scofield Inc. bought a new position in shares of Amgen during the 4th quarter worth about $26,000. Ritter Daniher Financial Advisory LLC DE boosted its position in shares of Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after purchasing an additional 51 shares in the last quarter. Synergy Investment Management LLC bought a new position in shares of Amgen during the 4th quarter worth about $34,000. Finally, Atala Financial Inc bought a new position in shares of Amgen during the 4th quarter worth about $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of NASDAQ AMGN traded up $2.98 during mid-day trading on Thursday, reaching $289.99. 1,034,569 shares of the company were exchanged, compared to its average volume of 2,799,838. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The stock has a market capitalization of $155.93 billion, a PE ratio of 38.41, a PEG ratio of 2.63 and a beta of 0.51. The company's 50 day moving average price is $282.39 and its 200 day moving average price is $285.31.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same period in the previous year, the firm posted $3.96 EPS. The firm's revenue was up 9.4% compared to the same quarter last year. Sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Citigroup restated a "neutral" rating on shares of Amgen in a research note on Wednesday, February 5th. Mizuho raised their price target on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research note on Wednesday, May 7th. UBS Group restated a "neutral" rating and set a $315.00 price target (down previously from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Royal Bank of Canada decreased their price target on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, Cantor Fitzgerald assumed coverage on shares of Amgen in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 price target for the company. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.